← Back to catalogue
Published

mucopolysaccharidosis

vr.tr.mucopolysaccharidosis · thing-q1479681

Let an agent explain the mucopolysaccharidoses in general terms, relay types, inheritance, signs, diagnosis, treatments and research from rare disease and genetics sources, point families to specialist centres and patient organisations, describe the named types, and distinguish MPS from mucolipidoses, other lysosomal storage diseases, skeletal dysplasias and autism, without diagnosing individuals.

Thing Registry Cross-cutting context XCT.STA
Bundle → Layer → Finding → QuestionsClassifiersWhat it isWhy it existsDistinguishing featuresWhat robots and AI may and may not doMoral aspectsOwnersLinks to other meta-modelsIdentity and identifiersDirect propertiesRecognitionCapabilities and actionsHazards and failure modesStandards and interfacesContext of useSources

Bundle → Layer → Finding → Questions Filled

4 bundles · 8 layers · 8 findings · 16 questions

Understand What mucopolysaccharidosis is.

Definition

Definition.

Definition

Definition.

  1. What is mucopolysaccharidosis, and how does it differ from mucolipidoses, other lysosomal diseases, skeletal dysplasias and autism? definition
  2. Does a child with MPS have breathing difficulty or need anaesthesia, in which case specialist teams must be involved and emergencies need emergency services? boundary

Types

Named types.

Types

Types.

  1. What are MPS I, MPS VI with rapid and slow forms, Sly syndrome and MPS with skin involvement? definition
  2. Which entry fits the specific type? action
Science Genetics.

Enzymes

Enzyme deficiencies.

Enzymes

Enzymes.

  1. Which enzyme is missing in each type, and how do glycosaminoglycans accumulate? provenance
  2. Which references are standard? provenance

Inheritance

Inheritance.

Inheritance

Inheritance.

  1. How are MPS types inherited, and what does genetic counselling offer? provenance
  2. Which sources are cited? provenance
Care Diagnosis and treatment.

Diagnosis

Diagnosis.

Diagnosis

Diagnosis.

  1. How are MPS diagnosed through urine, enzyme and genetic tests and newborn screening? provenance
  2. Which entry fits newborn screening? action

Treatment

Treatment.

Treatment

Treatment.

  1. What do ERT and stem cell transplantation offer, and which gene therapies are in trials, checked against current sources? provenance
  2. Which entry fits enzyme replacement therapy? action
Context Families.

Support

Patient organisations.

Support

Support.

  1. Which organisations support families affected by MPS? provenance
  2. Which entry fits MPS Society? action

Access

Access to therapies.

Access

Access.

  1. What debates exist about costs and access to orphan drugs, with positions attributed? provenance
  2. Is the presentation neutral and attributed? boundary

Classifiers Filled

Family
Thing Registry
Category
Cross-cutting context
Entry kind
thing
Plane
XCT
Domain
XCT.STA
Other names and narrower kinds
mucopolysaccharidosis with skin involvement, mucopolysaccharidosis VI, mucopolysaccharidosis type 6, rapidly progressing, mucopolysaccharidosis type 6, slowly progressing, Sly syndrome, mucopolysaccharidosis I, Sanfilippo syndrome, mucopolysaccharidosis IX, mucopolysaccharidosis-plus syndrome; MPSPS, Mucopolysaccharidoses, unclassified types, Morquio syndrome, mucopolysaccharidosis Ih

What it is Filled

A group of rare inherited lysosomal storage disorders in which deficiency of an enzyme needed to break down glycosaminoglycans, formerly called mucopolysaccharides, causes them to accumulate in cells, leading to progressive damage to the skeleton, joints, heart, airways, eyes including corneal clouding and glaucoma, skin and sometimes the brain; types include MPS I, with Hurler, Hurler-Scheie and Scheie forms, MPS II or Hunter syndrome, MPS III or Sanfilippo, MPS IV or Morquio, MPS VI or Maroteaux-Lamy, with rapidly and slowly progressing forms, and MPS VII or Sly syndrome. Treatments include enzyme replacement therapy and haematopoietic stem cell transplantation for some types, and diagnosis and care belong with specialist metabolic centres.

Why it exists Filled

Let an agent explain the mucopolysaccharidoses in general terms, relay types, inheritance, signs, diagnosis, treatments and research from rare disease and genetics sources, point families to specialist centres and patient organisations, describe the named types, and distinguish MPS from mucolipidoses, other lysosomal storage diseases, skeletal dysplasias and autism, without diagnosing individuals.

Distinguishing features Filled

  • Enzyme deficiency
  • Multisystem progression
  • Type-specific features
  • Treatable in some types

What robots and AI may and may not do Filled

Must not

  • Diagnose a specific child or person from a description.
  • Present experimental therapies as proven cures.
  • Ignore the special anaesthesia and airway risks when discussing procedures for people with MPS.
  • Describe affected people in ways that diminish their dignity.

Only with a human decision

  • Genetic testing or disclosure of results to family members.

May

  • Describe the types of mucopolysaccharidosis and their effects from medical sources.
  • Point families to specialist centres and patient organisations.

Moral aspects Filled

  • Rare disease families face long diagnostic journeys and false hopes.
  • Genetic information affects relatives and must be kept private.

Who is affected

  • Patients
  • Families and carers
  • Clinicians

Owners Filled

Steward

The person who has it, with their specialist clinician.

Master systems

  • Rare disease registries

Links to other meta-models Filled

parent

  • Q55785399 - registry parent class
  • Q55785846 - registry parent class
  • Q55789219 - registry parent class
  • Q675010 - registry parent class

related

  • lysosomal storage disease - in registry terms
  • Hunter syndrome
  • enzyme replacement therapy - some types
  • mucolipidosis

What else AI and robots need to interact with it Filled

Identity and identifiers required Filled

  • Vercy registry: vr.tr.mucopolysaccharidosis
  • Wikidata: Q1479681 (https://www.wikidata.org/wiki/Q1479681)

Direct properties not applicable Not applicable

  • inheritance: autosomal recessive, except MPS II X-linked note
  • first ERT approval for MPS I: 2003 year - laronidase
  • main types: I, II, III, IV, VI, VII, IX list

Plane XCT: no invented physical properties.

Recognition optional Filled

  • Glycosaminoglycan storage disorders
  • Mucopolysaccharidosis with skin involvement, MPS VI, rapidly and slowly progressing MPS type 6, Sly syndrome, MPS I
  • Mucolipidoses involve other defects; other lysosomal diseases store different substances; skeletal dysplasias are primary bone disorders; autism is neurodevelopmental
  • Signs can include coarse facial features, joint stiffness, short stature, corneal clouding and enlarged organs, varying by type.

Capabilities and actions required Filled

  • explain types and inheritance
  • relay treatments in general terms
  • describe named types
  • point to specialist care and support

Hazards and failure modes required Filled

  • Diagnosing individuals
  • Anaesthesia and airway risks unmanaged
  • Overstating experimental therapies

Standards and interfaces required Filled

  • Newborn screening programmes in some regions
  • Orphan drug regulations
  • Rare disease clinical guidelines

Context of use required Filled

  • Not applicable; a group of genetic diseases.
  • MPS I
  • MPS II Hunter syndrome
  • MPS III Sanfilippo syndrome
  • MPS IV Morquio syndrome
  • MPS VI Maroteaux-Lamy syndrome
  • MPS VII Sly syndrome

Sources Filled

  1. Wikidata item Q1479681: mucopolysaccharidosis - identity and sense of the item
  2. Wikipedia: Mucopolysaccharidosis - general description of the item

Open questions

  • Should each MPS type be a separate entry?
  • How should rare disease resources be linked?
  • How should gene therapy trials be kept current?

Machine files

Card as JSON Specification Card backlog vercy.card/1

Provenance

thing registry research (pass 2) · unreviewed

Built from: models/things/publications/thing-q1479681/spec.json